Hisamitsu Pharmaceutical Co (FRA:HPX) Retained Earnings: €1,245.5 Mil (As of Nov. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:HPX Hisamitsu Pharmaceutical Co Inc FRA:HPX
65 GF Score
Price €31.80
GF Value €25.90
View Full Analysis

What is Hisamitsu Pharmaceutical Co Retained Earnings?

Hisamitsu Pharmaceutical Co FRA:HPX 65 Retained Earnings is €1,245.5 Mil as of Nov. 2025. GuruFocus rates FRA:HPX with a GF Score™ of 65/100 and a GF Value™ of €25.90.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Hisamitsu Pharmaceutical Co's retained earnings for the quarter that ended in Nov. 2025 was €1,245.5 Mil.

Hisamitsu Pharmaceutical Co's quarterly retained earnings declined from May. 2025 (€1,574.4 Mil) to Aug. 2025 (€1,297.7 Mil) and declined from Aug. 2025 (€1,297.7 Mil) to Nov. 2025 (€1,245.5 Mil).

Hisamitsu Pharmaceutical Co's annual retained earnings increased from Feb. 2024 (€1,503.0 Mil) to Feb. 2025 (€1,633.3 Mil) but then declined from Feb. 2025 (€1,633.3 Mil) to Feb. 2026 (€1,258.1 Mil).


Hisamitsu Pharmaceutical Co  (FRA:HPX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Hisamitsu Pharmaceutical Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Retained Earnings Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,805.10 1,653.72 1,502.99 1,633.33 1,258.09

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,633.33 1,574.36 1,297.74 1,245.49 1,258.09
FRA:HPX
65GF Score
Hisamitsu Pharmaceutical Co Inc FRA:HPX
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €1,245.5 Mil mean?
Hisamitsu Pharmaceutical Co (FRA:HPX) has a Retained Earnings of €1,245.5 Mil as of Nov. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's Retained Earnings too high?
Hisamitsu Pharmaceutical Co's current Retained Earnings is €1,245.5 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Retained Earnings compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's Retained Earnings of €1,245.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current Retained Earnings is €1,245.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FRA:HPX) has a current Retained Earnings of €1,245.5 Mil. The stock's GF Value™ is €25.90, compared to a current price of €31.80 — trading 22.8% above its estimated fair value. The current Retained Earnings is €1,245.5 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 65/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FRA:HPX), the current Retained Earnings is €1,245.5 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FRA:HPX) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of €31.80 is trading 22.8% above its estimated GF Value™ of €25.90.

Key valuation signals for FRA:HPX:

  • Retained Earnings: €1,245.5 Mil
  • GF Value™: €25.90 vs. price of €31.80 (22.8% above fair value)
  • GF Score™: 65/100

No single metric tells the full story. See the FRA:HPX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
65GF Score

Get the complete analysis for FRA:HPX

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.80
Price
€25.90
GF Value